Nursing Considerations for Patients with Gout: Treatment and Management

Badr Aqeel H. Alshrari[1] ,Raedah Muqeem D. Alruwaili[2] ,Khaled Daifallah M. Alruwaili[3] ,Amal Azi Sayil Alruwaili[4] ,Alanazi Nadiyah Mahli M.[5] ,Marshad Abdullah Mashatil Alruwaili[6] ,Alrawili, Shouq Saud M.[7] ,Zamzam Nawaf Muidh Alshammari[8] , Alruwaili Shuruq Rahil F.[9] ,Salman Fahad Mohammad Al-Anizy[10]

[1] Senior Specialist-Primary Health Care Nursing - Nabk Abu Qasr Healthcare Center, Al-Jouf Health Cluster, Al-Jouf Region, Saudi Arabia
[2] Specialist Nursing - Prince Mutaib bin Abdulaziz Hospital, Sakaka, Al-Jouf Region, Saudi Arabia
[3] Nursing technician - Prince Mutaib bin Abdulaziz Hospital, Sakaka, Al-Jouf Region, Saudi Arabia
[4] Specialist Nursing - East Qara Health Center, Ministry of Health, Sakaka, Al-Jouf Region, Saudi Arabia
[5] Nursing technician - Prince Abdulaziz bin Musaed Hospital, Arar, Northern Borders Region, Saudi Arabia
[6] Nursing technician - Turaif General Hospital, Turaif, Northern Borders Region, Saudi Arabia
[7] Nursing and Midwifery - Prince Abdullah bin Abdulaziz bin Musaed Cardiac Center, Arar, Northern Borders Region, Saudi Arabia
[8] Technician-Nursing - Asfan Primary Health Care Center, Dumat Al-Jandal, Al-Jouf Region, Saudi Arabia
[9] Specialist Nursing - Eradah Mental Health Hospital, Al-Qurayyat, Al-Jouf Region, Saudi Arabia
[10] Nursing technician - Maternity and Children Hospital (MCH), Sakaka, Al-Jouf Region, Saudi Arabia

***Abstract*:**

Managing gout effectively requires a comprehensive nursing approach that focuses on both pharmacological and non-pharmacological interventions. Education is vital; nurses should inform patients about the nature of gout as a type of inflammatory arthritis caused by the accumulation of uric acid crystals in the joints. It's crucial to educate them about dietary modifications, such as reducing purine-rich foods (e.g., red meat, shellfish, and alcohol), which can exacerbate symptoms. Nurses should also emphasize the importance of staying well-hydrated to help flush uric acid from the body. Regular monitoring of serum uric acid levels is essential to evaluate treatment efficacy and adjust medications as needed. In terms of pharmacological management, nurses play a key role in administering and monitoring medications such as non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and urate-lowering therapies like allopurinol and febuxostat. It's important to watch for potential side effects, including gastrointestinal issues and allergic reactions, and to educate patients about when to seek medical attention. Psychosocial support is equally important, as gout can impact a patient's quality of life. Encouraging adherence to treatment plans, promoting self-management strategies, and offering empathetic support can help patients cope with the chronic nature of this condition.

***Keywords*:** Gout, Nursing considerations, Treatment, Management, Pharmacological interventions, Non-pharmacological interventions, Dietary modifications, Uric acid, Patient education, NSAIDs, Colchicine, Urate-lowering therapy, Serum uric acid monitoring, Side effects, Psychosocial support

Introduction:

Gout is an increasingly prevalent form of inflammatory arthritis characterized by recurrent episodes of acute pain and swelling, primarily affecting peripheral joints. It results from the deposition of monosodium urate crystals within the joint tissues due to hyperuricemia—a condition defined by elevated levels of uric acid in the blood. With an estimated 4% of the adult population in the United States diagnosed with gout, its prevalence is on the rise, coinciding with rising rates of obesity, metabolic syndrome, and dietary factors associated with uric acid production. As the burden of gout continues to escalate, understanding the multifaceted approaches required for its effective management is critical, particularly from a nursing perspective [1].

Nursing professionals play a vital role in the multidisciplinary management of gout, facilitating not only the pharmacological treatment but also the non-pharmacological approaches integral to patient care. Given the episodic nature of gout and its

profound impact on patients' quality of life, nursing considerations extend beyond the immediate alleviation of symptoms to encompass education, lifestyle modification, and long-term management strategies. Effective management of gout necessitates a comprehensive understanding of the condition's pathophysiology, the pharmacodynamics and pharmacokinetics of urate-lowering therapies, and the psychosocial implications that accompany chronic disease [2].

The management of gout involves various treatment modalities, including both acute and chronic therapies. Nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids are typically employed during gout flares to control inflammation and provide rapid relief. However, these medications must be carefully administered, often requiring nurses to assess renal function, potential drug interactions, and any contraindications that may exist within a patient's medical history. Furthermore, the use of urate-lowering therapy, such as allopurinol or febuxostat, presents its own set of considerations, particularly concerning regular monitoring for adverse effects and the need to gradually titrate dosages in order to minimize the risk of exacerbating acute attacks [3].

Nurses are also tasked with educating patients about the importance of lifestyle interventions, which can significantly reduce the frequency and severity of gout flares. Dietary modifications, fluid intake, weight management, and the reduction of alcohol consumption emerge as crucial non-pharmacological strategies. These considerations are particularly critical given that many patients may possess limited understanding of the disease or may have longstanding misconceptions about its management. Empowering patients with knowledge about their condition, including triggers for attacks and the importance of adherence to treatment regimens, is an essential nursing function that can lead to improved health outcomes [4].

Moreover, psychological stress and comorbid conditions, including hypertension, diabetes, and cardiovascular diseases, are often associated with gout. An effective nursing intervention must therefore include holistic assessments that consider these factors. Nurses can facilitate referrals to appropriate specialists, helping manage concomitant diseases while ensuring that the treatment for gout does not exacerbate other health issues. Interdisciplinary collaboration becomes crucial in developing tailored management plans that address the unique needs of patients living with gout [5].

As the role of nurses evolves within the complex healthcare landscape, the emphasis on evidence-based practice becomes a focal point of quality patient care. Several studies have sought to identify the most effective nursing interventions for individuals suffering from gout, highlighting the necessity for ongoing education and the integration of patient-reported outcomes in the management process. Understanding the patient's lived experience of gout can enhance clinical practice and promote patient-centered approaches that align with the overarching goals of healthcare [6].

Clinical Assessment and Diagnosis of Gout:

Gout is a form of inflammatory arthritis characterized by sudden and severe episodes of pain, redness, and swelling in the joints, frequently affecting the big toe. This condition is primarily caused by hyperuricemia, a condition in which there is an excess of uric acid in the blood, leading to the formation of monosodium urate crystals that deposit in the joints and surrounding tissues. The clinical assessment and diagnosis of gout are vital to ensure accurate management and prevent long-term joint damage [7].

The clinical presentation of gout typically involves acute attacks, which can occur suddenly, often at night. Patients frequently report severe pain, swelling, and tenderness in affected joints, commonly starting in the metatarsophalangeal joint of the big toe, a condition historically known as "podagra." These acute episodes can last for several days to weeks and may recur, particularly in the absence of treatment [8].

Between gout attacks, patients may be asymptomatic; however, chronic hyperuricemia can lead to the development of tophi, which are deposits of urate crystals that can form under the skin and in joints, causing further complications. Other common sites for gout attacks include the ankle, knee, and elbow. The presence of these tophi and chronic joint inflammation can lead to a significant decline in the quality of life for affected individuals [9].

Additional clinical features may include fever, malaise, and generalized discomfort during gout

flares. Risk factors for the development of gout include obesity, excessive alcohol consumption, high-purine diets rich in red and organ meats, certain medications such as diuretics, and renal impairment, which decreases uric acid excretion [10].

Diagnostic Criteria

The diagnosis of gout is primarily based on clinical evaluation and is supported by laboratory findings. The American College of Rheumatology (ACR) has established criteria for the classification of gout, which include:

1. **Presence of Hyperuricemia**: A serum uric acid level above 6.8 mg/dL is considered hyperuricemic. Although not all hyperuricemic patients will develop gout, elevated levels are a significant indicator.

2. **Clinical Symptoms**: Patients typically present with at least one attack of inflammatory arthritis, characterized by rapid onset, severe pain, and joint swelling.

3. **Exclusion of Other Causes**: The diagnosis of gout requires the exclusion of other potential causes of arthritis or joint pain, including infections, other inflammatory arthritis types, and crystal arthropathies.

4. **Presence of Monosodium Urate Crystals**: Identification of urate crystals in synovial fluid or tophi is definitive for diagnosis. This can be achieved through joint aspiration (arthrocentesis) during an acute phase of the disease, wherein fluid is collected and analyzed under polarized light microscopy [11].

Laboratory Testing

Laboratory tests play a crucial role in confirming the diagnosis of gout. Serum uric acid levels are routinely checked; however, it is worth noting that a normal serum uric acid level does not completely rule out gout, as levels may fluctuate during an attack. To further substantiate the diagnosis, the following laboratory tests may be employed:

- **Arthrocentesis**: This involves the aspiration of synovial fluid from the affected joint for crystal analysis. The presence of negatively birefringent needle-shaped crystals under polarized light microscopy confirms gout [12].
- **Blood Tests**: In addition to measuring uric acid levels, complete blood counts (CBC) and inflammatory markers (such as erythrocyte sedimentation rate [ESR] or C-reactive protein [CRP]) may be evaluated to assess for systemic inflammation and rule out other conditions.
- **24-Hour Urine Collection**: In certain cases, a 24-hour urine uric acid test may be conducted to assess kidney excretion of uric acid and determine whether the hyperuricemia is due to overproduction or underexcretion [12].

Imaging Techniques

Imaging studies can be instrumental in assessing the extent of joint involvement in gout, especially for chronic cases.

- **X-rays**: In patients with chronic gout, X-rays can reveal characteristic "punched-out" erosions in bone near the joints. However, these changes may take years to develop and are not typically seen during acute attacks.
- **Ultrasound**: Musculoskeletal ultrasound can be utilized to detect the presence of tophi and synovial thickening, providing a non-invasive option to visualize crystal depositions.
- **Dual-Energy Computed Tomography (DECT)**: This advanced imaging technique allows for the visualization of urate crystal deposits and has emerged as a helpful diagnostic tool, although it is less widely available [13].

Differential Diagnosis

Differentiating gout from other forms of arthritis is essential for appropriate management. Conditions to consider include:

- **Pseudogout (calcium pyrophosphate dihydrate crystals)**: This condition mimics gout but is caused by the deposition of calcium pyrophosphate crystals. A similar acute presentation can occur, but the crystals are positively birefringent under polarized light.
- **Septic Arthritis**: This can present with acute joint swelling and pain but is typically accompanied by systemic signs of infection. Synovial fluid analysis showing white blood cell predominance and the presence of microorganisms would support this diagnosis.

- **Rheumatoid Arthritis**: Characterized by a symmetrical polyarthritis, laboratory findings will often reveal rheumatoid factor or anti-citrullinated protein antibodies, distinguishing it from gout.
- **Other Conditions**: Inflammatory conditions such as ankylosing spondylitis, psoriatic arthritis, and reactive arthritis should also be considered based on the clinical presentation and patient history [14].

Pharmacological Management: Medications and Protocols:

Gout is a complex form of inflammatory arthritis characterized by the deposition of monosodium urate crystals in joints, often leading to sudden and severe episodes of pain, swelling, and redness. It stems primarily from hyperuricemia, a condition marked by elevated levels of uric acid in the blood. Effective pharmacological management is critical for alleviating acute gout attacks, controlling chronic gout, and preventing complications associated with sustained hyperuricemia [15].

Gout can be categorized into two main phases: acute gout attacks and chronic gout management. Acute attacks typically occur suddenly and may resolve within days to weeks. Chronic gout, on the other hand, is marked by recurring attacks and persistent urate levels that necessitate a more sustained management approach.

The role of metaphyseal joints and tissues in the pathophysiology of gout is essential for understanding treatment strategies. During acute inflammatory episodes, the innate immune system is activated, which incurs a cascade of immune responses resulting in pain and swelling. A comprehensive treatment protocol must, therefore, address both immediate alleviation of symptoms during acute flares and the longer-term strategy of uric acid lowering to prevent future episodes [15].

Medications for Acute Gout Attacks

1. **Non-Steroidal Anti-Inflammatory Drugs (NSAIDs):**
NSAIDs are often the first line of treatment for acute gout attacks. They reduce inflammation and are effective in alleviating pain. Popular options include indomethacin, naproxen, and ibuprofen. Typically, treatment is initiated at higher doses to manage pain and then tapered as the symptoms improve. A major advantage of NSAIDs is their rapid action against inflammation; however, potential side effects such as gastrointestinal bleeding, renal impairment, and cardiovascular risks must be considered, particularly in patients with pre-existing conditions [16].

2. **Colchicine:**
Colchicine is another cornerstone in the management of acute gout. It functions by inhibiting microtubule polymerization, thus interfering with the activation and migration of neutrophils to sites of inflammation. Colchicine is particularly recommended for patients who cannot tolerate NSAIDs. Though effective, its utilization demands careful dosing due to the risk of gastrointestinal side effects, including diarrhea and nausea.

3. **Corticosteroids:**
For patients who are unable to take NSAIDs or colchicine, corticosteroids such as prednisone provide a viable alternative for managing acute gout attacks. They are especially useful in patients with comorbidities that may contraindicate the use of NSAIDs. Corticosteroids can be administered orally or via intra-articular injection, delivering targeted relief [16].

Long-term Management: Uric Acid-Lowering Therapies

After controlling acute symptoms, the chronic management of gout focuses on lowering serum uric acid levels to prevent future flare-ups. This involves pharmacological approaches that address the underlying hyperuricemia [17].

1. **Xanthine Oxidase Inhibitors (XOIs):**
Allopurinol is the most commonly prescribed medication in this category and acts by inhibiting the xanthine oxidase enzyme, which reduces uric acid production. Initially, it was. This option benefits patients with recurrent attacks or those at risk of complications due to high uric acid levels. Care must be taken in initiating treatment, as a rapid reduction in uric acid levels can paradoxically trigger acute attacks; thus, a conservative approach with slow titration of the dose is often recommended [17].

Febuxostat is another xanthine oxidase inhibitor that is considered when patients experience intolerance to allopurinol. It offers similar efficacy in lowering uric acid but may be more useful in certain populations [18].

2. **Uricosuric Agents:**
These agents, including probenecid and lesinurad,

enhance renal excretion of uric acid. Probenecid is particularly useful in underexcreters of uric acid, helping to normalize serum levels. Lesinurad is often used in conjunction with XOIs to further improve uric acid excretion and can be advantageous in patients with refractory hyperuricemia [18].

3. **Pegloticase:**

For patients with treatment-resistant gout or those suffering from severe chronic gout (such as tophi), pegloticase—a monoclonal antibody—can be a last-resort option. It works by enzymatically converting uric acid into allantoin, an easily excretable compound. Its intravenous administration and cost make it less frequently utilized, but it can be invaluable for patients who fail other therapies [18].

Additional Considerations in Gout Management

Patient education remains a vital component in the effective management of gout. Engaging patients in discussions about lifestyle modifications—such as dietary changes that encourage the reduction of purine intake, alcohol consumption moderation, and weight management—can enhance the effectiveness of pharmacological interventions.

Moreover, long-term management may involve periodic monitoring of serum uric acid levels and renal function, ensuring that treatments remain effective and that side effects are managed proactively [19].

Non-Pharmacological Interventions: Lifestyle and Dietary Modifications:

Gout is a type of inflammatory arthritis characterized by the accumulation of urate crystals in the joints, leading to episodes of acute pain, swelling, and redness. While pharmacological treatments such as non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and urate-lowering medications are commonly employed to manage gout symptoms and prevent future attacks, there is a growing recognition of the role non-pharmacological interventions can play. Among these interventions, lifestyle and dietary modifications are particularly significant, as they can help reduce uric acid levels, alleviate symptoms, and enhance the overall quality of life for individuals with gout [20].

Gout arises from hyperuricemia, a condition characterized by elevated levels of uric acid in the blood. This hyperuricemia can result from increased production, decreased excretion of uric acid, or a combination of both. Uric acid is a product of purine metabolism; purines are substances found in various foods and drinks, as well as in the body's own cells. When urate levels exceed the saturation threshold in the blood, urate crystals can form and deposit in joints. This deposition prompts an inflammatory response, leading to the characteristic painful flare-ups [20].

Given this metabolic context, interventions aimed at managing uric acid levels through lifestyle and dietary changes become crucial. Understanding the mechanisms of gout allows patients and healthcare providers to target specific behaviors and food choices that could mitigate the risks associated with the condition.

Obesity is a significant risk factor for the development of gout due to its association with increased uric acid production and decreased renal clearance of urate. Therefore, weight reduction can profoundly impact the frequency and severity of gout attacks. Even a modest weight loss of 5-10% can result in significant improvements in uric acid levels. A balanced approach combining regular physical activity with a calorie-restricted diet can promote sustained weight loss. Exercise contributes not only to weight management but also improves cardiovascular health, which is often compromised in patients with gout [21].

Regular physical activity is essential not only for weight management but also for overall joint health. Exercise can help reduce inflammation, improve joint function, and lower the risk of comorbidities associated with gout, such as hypertension, diabetes, and cardiovascular disease. Low-impact activities, such as swimming, cycling, and walking, are particularly recommended, as they are less likely to exacerbate joint pain. Patients should aim for at least 150 minutes of moderate-intensity exercise per week, ensuring to engage in flexibility and strengthening exercises to maintain joint and muscle function [21].

Maintaining proper hydration is vital for gout management as it aids in renal function and helps decrease uric acid concentration in the blood. Drinking plenty of water facilitates the excretion of uric acid through the kidneys. Patients are advised to consume at least 8-12 cups of fluids daily, with a

focus on water as the primary source. Alcohol, especially beer and distilled spirits, should be limited, as they can trigger uric acid production and impair its elimination [21].

Dietary Modifications

Diet plays a critical role in managing and preventing gout attacks. Making informed dietary choices can help reduce uricaemia and improve overall health [22].

1. Limiting Purine-Rich Foods

Purine-rich foods contribute to increased uric acid production, and thus, gout patients are often advised to limit their intake. High-purine foods include red meats, organ meats (such as liver and kidney), and certain types of seafood, such as sardines and anchovies. Instead, patients should adopt a diet rich in low-purine foods, which include dairy products, vegetables, fruits, and whole grains [22].

2. Emphasizing Plant-Based Proteins

Switching from animal-based to plant-based sources of protein can also aid in managing gout. Foods such as nuts, lentils, beans, and tofu provide adequate protein without the accompanying purine load found in many animal products. Research has suggested that the consumption of low-fat dairy products may even be beneficial, potentially helping to lower uric acid levels and reduce the risk of gout attacks [22].

3. Incorporating Fruits and Vegetables

A diet high in fruits and vegetables is associated with a lower risk of gout. Cherries, in particular, have been extensively studied for their potential role in reducing uric acid levels and lowering the frequency of gout flares. Their high antioxidant content, particularly anthocyanins, is thought to be responsible for their anti-inflammatory properties. Other fruits, such as berries, oranges, and kiwi, also contribute similarly to health benefits. As for vegetables, while some high-purine vegetables like asparagus and mushrooms may be mentioned, they do not appear to significantly increase the risk of gout and can be consumed in moderation [23].

4. Reducing Sugar Intake

The consumption of sugar, particularly fructose, has been linked to an increased risk of gout attacks. Fructose is found in sugary beverages, fruit juices, and processed foods. Therefore, limiting the intake of these items can be a prudent strategy for gout patients. Replacing high-fructose beverages with water, herbal teas, or other non-sweetened drinks can bolster hydration and reduce uric acid levels [23].

Monitoring and Management of Comorbidities in Patients with Gout:

Gout is a common form of inflammatory arthritis characterized by the deposition of monosodium urate crystals in the joints due to elevated levels of serum uric acid. Although often perceived as a singular condition, gout frequently coexists with comorbidities that can complicate its treatment and management. These comorbidities encompass various health issues, such as obesity, diabetes mellitus, hypertension, chronic kidney disease (CKD), and cardiovascular disease. Due to their prevalence among gout sufferers, effective monitoring and management of these comorbidities are essential components of comprehensive care [24].

Understanding Gout and Its Comorbidities

Gout is primarily driven by hyperuricemia, which occurs when uric acid levels exceed the normal physiological range due to factors such as dietary choices, genetic predisposition, and certain medications. Clinical manifestations include acute attacks of arthritis, chronic joint pain, and the formation of tophi, which are crystal deposits that aggregate in tissues. The impact of gout extends beyond joint pain, as it has a significant association with a range of metabolic and cardiovascular conditions [24].

1. Obesity: Obesity is one of the most common comorbidities in patients with gout. Increased body weight contributes to higher uric acid production and decreased renal clearance. The association between obesity and the severity of gout flares is well-documented. The inflammatory state associated with obesity may synergistically exacerbate gouty arthritis [25].

2. Diabetes Mellitus: The relationship between gout and type 2 diabetes mellitus is bidirectional; patients with diabetes are more likely to develop gout, while those with gout face a higher risk of developing diabetes. Insulin resistance, which is prevalent in diabetic patients, negatively affects

renal handling of uric acid, leading to hyperuricemia [25].

3. Hypertension: Hypertension often coexists with gout, and studies indicate that individuals with gout are at an increased risk for developing high blood pressure. The use of medications such as thiazide diuretics for hypertension can further elevate uric acid levels, creating a challenging scenario for management [26].

4. Chronic Kidney Disease (CKD): CKD complicates gout management significantly because reduced renal function hinders the excretion of uric acid. Conversely, gout can contribute to the progression of kidney disease due to the deposition of urate crystals in the nephrons, further impeding kidney function [26].

5. Cardiovascular Disease: Gout is a recognized independent risk factor for cardiovascular disease. The underlying inflammatory mechanisms, as well as shared risk factors such as obesity, hypertension, and hyperlipidemia, tie gout to an increased risk of heart attacks and strokes.

Monitoring Comorbidities in Gout Patients

The management of gout necessitates a holistic approach, particularly regarding the monitoring of comorbidities. Regular assessments of these conditions not only help tailor treatment strategies but also minimize the risk of complications [26].

1. Regular Health Check-ups: Patients with gout should have routine check-ups that include monitoring body weight, body mass index (BMI), waist circumference, blood pressure, renal function (including serum creatinine), and serum uric acid levels. Comprehensive metabolic panels can provide critical insights into lipid profiles and glucose levels, helping to identify diabetes and dyslipidemia early.

2. Rheumatology and Primary Care Collaboration: Coordination between rheumatologists and primary care providers is crucial. Both specialties can work collaboratively to create individualized management plans that address not just gout treatment but also the interconnected problems posed by comorbidities [27].

3. Patient Education and Self-Monitoring: Educating patients about their conditions and the importance of self-monitoring is vital for successful management. Patients should be informed about dietary choices that can exacerbate uric acid levels, such as purine-rich foods and alcohol intake. Additionally, they should be encouraged to monitor symptoms of gout and comorbidities, alerting healthcare providers as necessary [27].

Management Strategies for Comorbidities

Effective management of comorbid conditions in gout patients revolves around lifestyle modifications, pharmacological interventions, and interdisciplinary care.

1. Lifestyle Modifications: Addressing obesity through weight loss programs is critical, as lose just 5-10% of body weight can lead to significant reductions in uric acid levels. Dietary interventions focusing on a balanced diet low in purines and saturated fats, rich in fruits, vegetables, and whole grains, are essential. Moreover, physical activity should be encouraged to improve overall metabolic health and reduce inflammation [27].

2. Pharmacologic Interventions: When dealing with hypertension and diabetes, careful selection of medications is necessary. For hypertensive patients, alternatives to thiazide diuretics, such as angiotensin-converting enzyme (ACE) inhibitors, may be preferred owing to their neutral effect on uric acid levels. Diabetic patients may benefit from medications that also impact uric acid metabolism positively, such as SGLT2 inhibitors. Additionally, urate-lowering therapies such as allopurinol or febuxostat can be initiated to maintain serum uric acid below target levels and prevent gout flares [28].

3. Comprehensive Multidisciplinary Management: Establishing a care team that includes a primary care physician, a rheumatologist, a nutritionist, and, if necessary, an endocrinologist or cardiologist enhances treatment efficacy. Regular interdisciplinary meetings can ensure that all aspects of a patient's health are addressed cohesively [28].

Patient Education and Self-Management Strategies:

Gout is a form of inflammatory arthritis characterized by sudden and severe episodes of pain, swelling, and redness, typically in the joints. It occurs when there is an excessive concentration of uric acid in the blood, resulting in the formation of urate crystals that accumulate in joints and surrounding tissues. Gout affects millions

worldwide and often leads to chronic pain, physical limitations, and decreased quality of life if not properly managed. Consequently, patient education and self-management strategies are critical tools in effectively managing gout and minimizing its impact on daily living [29].

To effectively manage gout, patients must first thoroughly understand the condition. Gout is classified as a type of arthritis and is a result of a metabolic disorder characterized by the overproduction or underexcretion of uric acid. Normal blood uric acid levels typically range from 2.4 to 6.0 mg/dL in women and 3.4 to 7.0 mg/dL in men. When levels exceed this range, there is a risk of crystal formation in the joints, which leads to painful gout flares. Risk factors for developing gout include obesity, a diet high in purines (found in certain meats, seafood, and alcoholic beverages), a sedentary lifestyle, and certain medical conditions such as hypertension and diabetes [29].

Patient education is paramount in empowering individuals with gout to take control of their health. Educating patients about the nature of gout, its causes, risk factors, and treatment options equips them with the knowledge they need to make informed decisions about their health. Healthcare providers should discuss the disease process, the importance of uric acid level monitoring, and potential complications of inadequately controlled gout, such as joint damage and the development of tophi—hard deposits of uric acid that form under the skin [29].

A significant component of patient education involves instilling the importance of medication adherence. Patients should be made aware of the medications prescribed for gout, including anti-inflammatory drugs, colchicine, and urate-lowering therapy like allopurinol or febuxostat. It is important that they understand how these medications work, their potential side effects, and the necessity of lifelong adherence in cases of recurrent gout [30].

A key aspect of self-management strategies for patients with gout lies in dietary modifications. Diet plays a critical role in uric acid production and elimination. The primary recommendation is to limit the intake of purine-rich foods, which can contribute to elevated uric acid levels. Foods high in purines include red meat, organ meats, certain seafood (like sardines, anchovies, and scallops), and high-fructose corn syrup found in many sugary drinks and processed foods [30].

Patients are encouraged to adopt a well-balanced diet that emphasizes whole grains, fruits, vegetables, low-fat dairy products, and lean proteins. Certain foods, such as cherries and vitamin C-rich foods, may also have a uric acid-lowering effect. Staying well-hydrated is crucial, and patients should aim for at least 8-12 cups of fluids per day, with an emphasis on water [30].

Beyond dietary adjustments, broader lifestyle modifications can contribute significantly to managing gout symptoms. Weight management is particularly imperative, as obesity is a major risk factor for joint strain and can prevent adequate excretion of uric acid. A gradual and sustained weight loss of 1-2 pounds per week is generally recommended, as rapid weight loss can lead to increased uric acid levels [30].

Regular physical activity is essential not only for weight control but also for overall health. Low-impact exercises such as swimming, walking, and cycling can help maintain joint mobility and function, while strength training can boost metabolism and encourage weight maintenance.

Moreover, patients should be proactive in avoiding triggers known to provoke gout attacks, such as excessive alcohol consumption—especially beer and liquor—and high-intensity workouts during flare-ups. Instead, moderate exercise is encouraged, allowing for a balance between physical activity and rest [31].

Self-management strategies must include regular monitoring of uric acid levels, as this helps in evaluating the effectiveness of treatment plans and dietary changes. Patients should keep a journal to document their diet, exercise, medication adherence, and any episodes of pain or swelling. This information can be invaluable in identifying personal patterns and triggers, as well as providing healthcare providers with insights into the patient's overall management plan [32].

Regular follow-up appointments with healthcare providers are crucial for managing gout effectively. During these visits, healthcare providers can assess the patient's progress, adjust medications if necessary, and reinforce education regarding gout management.

Support systems, including patient education groups and support networks, can provide substantial encouragement for individuals living with gout. Engaging with others who share similar experiences can provide emotional support, motivation, and practical advice for managing daily challenges associated with gout [32].

Additionally, many communities have resources such as diabetes or arthritis foundations that offer informational workshops, dietary classes, and online forums, where patients can access up-to-date research and evidence on gout management [33].

Psychosocial Aspects of Living with Gout: Support and Counseling:

Gout is a form of inflammatory arthritis characterized by sudden and severe pain, redness, and swelling in the joints, often affecting the big toe. While the physical symptoms of gout are well-documented, the psychosocial impact of living with this chronic condition is equally significant and often overlooked. The experience of managing gout involves not only physical pain but also emotional distress, social isolation, and lifestyle adjustments [33].

Before delving into the psychosocial implications, it is essential to understand the basic nature of gout. Gout is primarily caused by the accumulation of urate crystals in the joints due to high levels of uric acid in the blood. Factors contributing to this condition include dietary choices, genetics, obesity, and certain medications. The unpredictable flare-ups can be debilitating, leading to not only physical pain but also emotional and social challenges [33].

Living with a chronic condition like gout can lead to significant emotional strain. Individuals often experience anxiety and depression, particularly in relation to the fear of recurrent attacks. The unpredictability of gout flares makes it difficult for individuals to plan activities or engage in social events. This uncertainty can foster feelings of helplessness and frustration, as patients may feel they are at the mercy of their condition [34].

The pain associated with gout can also lead to chronic stress, contributing to a cycle of physical and mental health deterioration. Stress, in turn, can elevate uric acid levels, leading to more frequent gout attacks. Many patients report feeling embarrassed about their condition, especially if the flare-up occurs in social settings, further exacerbating their emotional burden [34].

The psychosocial aspects of gout can lead to social isolation. Patients may avoid social gatherings where food and drink are central, fearing that their dietary restrictions and potential need for medication will set them apart from their peers. This self-imposed isolation can intensify feelings of loneliness, and as time goes on, individuals may withdraw from relationships and activities they once enjoyed [35].

Additionally, the stigma around the condition can further alienate individuals. Misunderstandings about gout being solely related to excessive alcohol consumption or poor lifestyle choices may lead to negative perceptions, making it harder for individuals with gout to seek support and understanding from friends and family [36].

The role of support systems in managing the psychosocial impacts of gout cannot be overstated. Friends, family, and healthcare providers can play a crucial role in providing emotional and practical support. Understanding from loved ones can mitigate feelings of loneliness and frustration that often accompany chronic illnesses [36].

Support groups, either in person or online, can provide an empathetic space for individuals with gout to share their experiences, coping strategies, and advice on managing the condition. Such communal settings allow patients to understand that they are not alone in their battle and can foster a sense of belonging [37].

Counseling can be a vital resource for individuals living with gout. Mental health professionals can assist patients in developing coping strategies for managing both the physical pain and emotional distress associated with the condition. Cognitive-behavioral therapy (CBT) is one effective approach that can help individuals reframe negative thoughts associated with their condition, reduce anxiety, and build resilience [38].

Additionally, educational counseling can provide patients with essential information about gout management, including dietary adjustments and lifestyle modifications that can help control symptoms. This holistic approach not only addresses the emotional components of living with gout but also empowers individuals with knowledge and

tools to manage their physical health proactively [39].

Healthcare providers have a central role in addressing the psychosocial aspects of gout management. They should adopt a comprehensive approach that goes beyond treating the physical symptoms to include inquiries about the emotional well-being of patients. Regular assessments of mental health, encouragement to participate in support groups, and open discussions about the psychosocial challenges of gout should become an essential part of care protocols [40].

Incorporating a multidisciplinary team, including dietitians, occupational therapists, and physical therapists, can enhance the management of gout. Each professional can contribute unique insights that address various aspects of the condition and its impact on the patient's life [41].

Future Directions in Gout Management and Nursing Implications:

Gout, a form of inflammatory arthritis, has historically been a condition intertwined with lifestyle, diet, and genetics. Characterized by the accumulation of urate crystals in the joints, gout causes intermittent flares of severe pain, swelling, and tenderness, primarily affecting the big toe, but it can also impact other joints. With advancing understanding of the disease, its management is evolving, providing an opportunity to explore future directions that may significantly enhance patient outcomes. The role of nursing in gout management is crucial as well, as nurses often serve as the first point of contact for patients and are instrumental in providing education, care coordination, and support [42].

Before delving into future directions for gout management, it is critical to understand current treatment modalities. Traditional approaches to managing gout primarily involve both pharmacologic and non-pharmacologic strategies. Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for acute attacks, alongside corticosteroids and colchicine. For long-term management of hyperuricemia—elevated uric acid levels—urate-lowering therapies (ULT) such as allopurinol and febuxostat are routinely utilized. Lifestyle modifications—including dietary changes, weight management, and alcohol reduction—also play an integral role in managing gout [43].

Despite these established methods, the prevalence of gout is on the rise, resulting in an urgent need for more effective management strategies. The increasing incidence is attributed to factors such as aging populations, rising obesity rates, and increased consumption of purine-rich diets. Hence, healthcare systems must evolve to better address the growing burden of gout [44].

The future of gout management will inevitably lean towards patient-centered care, driven by shared decision-making and individualized therapy. Understanding patient preferences, values, and lifestyle choices will enable healthcare professionals to develop personalized treatment plans. For instance, patients may be more adherent to long-term ULT if they are actively involved in discussions surrounding their treatment, including considerations regarding side effects and the long-term benefits of urate-lowering strategies. Nurses are pivotal in these discussions; their ability to build therapeutic relationships can foster open communication and enhance patient engagement in their healthcare [45].

As the understanding of gout pathophysiology evolves, novel therapeutic options are emerging. The introduction of biologics, such as interleukin-1 inhibitors (e.g., anakinra, canakinumab), provides new avenues for gout management, particularly in patients with recurrent flares not adequately managed by conventional therapies. These agents work by specifically targeting the inflammatory pathways implicated in gout attacks. Their potential use reflects a broader trend in medicine towards precision and targeted therapies, which aims to maximize efficacy while minimizing adverse effects [46].

In the realm of ULT, emerging agents such as lesinurad and pegloticase offer promise for patients who are refractory to traditional treatments. These new medications can cater to diverse patient needs, particularly in those with comorbid conditions where conventional agents may pose risks. As these therapies become available, nurses must remain informed and adept at educating patients regarding new options, potential benefits, and possible adverse effects [47].

In the coming years, the integration of technology into gout management presents considerable potential. Wearable devices and mobile applications

can facilitate real-time monitoring of symptoms, medication adherence, and lifestyle modifications. These technologies empower patients to take ownership of their health while providing healthcare providers with valuable data to inform treatment adjustments [48].

For example, mobile health applications can allow patients to input their uric acid levels, dietary habits, and physical activity, creating a comprehensive picture that can guide therapeutic decisions. Through telehealth platforms, patients can receive timely consultations, follow-up care, and education, offering an alternative solution for those facing barriers to accessing traditional healthcare [49].

Nurses stand to benefit enormously from such technological advancements. By utilizing these tools, they can enhance patient education, monitor disease progress, and encourage adherence to treatment plans, ultimately leading to better outcomes in gout management [50].

A pivotal aspect of future directions in gout management involves ongoing education—both for patients and healthcare professionals. As new research emerges, staying updated on the latest guidelines and treatment strategies is essential for all stakeholders involved in gout care. Nurses not only need to educate their patients about the nature of gout and the importance of treatment adherence but also advocate for increased awareness surrounding the condition [51].

Raising awareness about gout is especially critical due to the stigma often associated with the disease, which can deter people from seeking timely treatment. Public health education campaigns can promote understanding of the condition as a treatable chronic illness rather than a mere consequence of poor lifestyle choices [52].

Conclusion:

In conclusion, effective nursing considerations for patients with gout are essential for optimizing treatment outcomes and enhancing quality of life. A comprehensive approach that encompasses both pharmacological and non-pharmacological strategies is critical in managing this chronic condition. Nurses play a pivotal role in providing patient education, emphasizing the importance of lifestyle and dietary modifications, and ensuring adherence to prescribed medication regimens. Regular monitoring of uric acid levels and comorbid conditions further supports effective management and helps prevent exacerbations.

Moreover, addressing the psychosocial dimensions of living with gout is crucial for holistic patient care. By fostering strong therapeutic relationships, nurses can encourage open dialogue and empower patients to engage actively in their health management. As our understanding of gout continues to evolve, ongoing research and education will be vital in refining nursing practices and improving care strategies. Ultimately, a patient-centered approach that prioritizes education, support, and individualized care will significantly enhance the management of gout, leading to better health outcomes and improved patient satisfaction.

References:

1. McLachlan A, Kerr A, Lee M, Dalbeth N. Nurse-led cardiovascular disease risk management intervention for patients with gout. Eur J Cardiovasc Nurs. 2011;10:94–100. doi: 10.1016/j.ejcnurse.2010.05.001.
2. Hellings P, Howe C. Breastfeeding knowledge and practice of pediatric nurse practitioners. J Pediatr Health Care. 2004;18:8–14. doi: 10.1016/s0891-5245(03)00108-1.
3. Fuller A, Jenkins W, Doherty M, Abhishek A. Nurse-led care is preferred over GP-led care of gout and improves gout outcomes: Results of Nottingham gout treatment trial follow-up study. Rheumatology (Oxford) 2020;59:575–579. doi: 10.1093/rheumatology/kez333.
4. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: A qualitative study. Ann Rheum Dis. 2012;71:1490–1495. doi: 10.1136/annrheumdis-2011-200801.
5. Deprouw C, Guignot M, Bougeois-Sarran C, Bougeois-Sarran C, Coblentz-Baumann L, Ea HK. Partners and nurses' knowledge and representations of gout: A qualitative study. Joint Bone Spine. 2019;86:769–776. doi: 10.1016/j.jbspin.2019.04.010.
6. Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, Barclay C, Doherty S, Duley L, Hatton R, et al. Efficacy and cost-effectiveness of nurse-led care

involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: A randomised controlled trial. Lancet. 2018;392:1403–1412. doi: 10.1016/S0140-6736(18)32158-5.

7. Rai SK, Choi HK, Choi SHJ, Townsend AF, Shojania K, De Vera MA. Key barriers to gout care: A systematic review and thematic synthesis of qualitative studies. Rheumatology (Oxford) 2018;57:1282–1292. doi: 10.1093/rheumatology/kex530.
8. Erwin J, Edwards K, Woolf A, Whitcombe S, Kilty S. Better arthritis care: What training do community-based health professionals need to improve their care of people with arthritis? A Delphi study. Musculoskeletal Care. 2018;16:48–59. doi: 10.1002/msc.1202.
9. Abhishek A, Jenkins W, La-Crette J, Fernandes G, Doherty M. Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study. Rheumatology (Oxford) 2017;56:529–533. doi: 10.1093/rheumatology/kew395.
10. Latif ZP, Nakafero G, Jenkins W, Doherty M, Abhishek A. Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care. Joint Bone Spine. 2019;86:357–362. doi: 10.1016/j.jbspin.2018.10.008.
11. Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK. Gout. Nat Rev Dis Primers. 2019;5(69) doi: 10.1038/s41572-019-0115-y.
12. Chua XHJ, Lim S, Lim FP, Lim YNA, He HG, Teng GG. Factors influencing medication adherence in patients with gout: A descriptive correlational study. J Clin Nurs. 2018;27:e213–e222. doi: 10.1111/jocn.13918.
13. Seow LL, Jiao N, Wang W, Holroyd E, Teng GG, He HG. A qualitative study exploring perceptions of patients with gout. Clin Nurs Res. 2020;29:56–65. doi: 10.1177/1054773818769219.
14. Mirmiran R, Bush T, Cerra MM, Grambart S, Kauschinger E, Younger M, Zychowicz M. Joint clinical consensus statement of the American college of foot and ankle surgeons® and the American association of nurse practitioners®: Etiology, diagnosis, and treatment consensus for gouty arthritis of the foot and ankle. J Foot Ankle Surg. 2018;57:1207–1217. doi: 10.1053/j.jfas.2018.08.018.
15. Hellings P, Howe C. Breastfeeding knowledge and practice of pediatric nurse practitioners. J Pediatr Health Care. 2004;18:8–14. doi: 10.1016/s0891-5245(03)00108-1.
16. Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One. 2012;7(11):e50046. doi: 10.1371/journal.pone.0050046.
17. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991–F997. doi: 10.1152/ajprenal.00283.2001.
18. Mihai S, Codrici E, Popescu ID, et al. Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome. J Immunol Res. 2018;2018:1–16. doi: 10.1155/2018/2180373.
19. Linnane JW, Burry AF, Emmerson BT. Urate deposits in the renal medulla. Nephron. 1981;29(5-6):216–222. doi: 10.1159/000182373.
20. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17(1):90. doi: 10.1186/s13075-015-0610-9.
21. Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E. Chronic kidney disease in gout in a managed care setting. BMC Nephrol. 2011;12(1):36. doi: 10.1186/1471-2369-12-36.
22. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilization in US veterans. Ann Rheum Dis. 2007;67(9):1310–1316. doi: 10.1136/ard.2007.081604.
23. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination

survey 2007-2008. Arthritis Rheum. 2011;63(10):3136–3141. doi: 10.1002/art.30520.

24. Jaffe DH, Klein AB, Benis A, et al. Incident gout and chronic kidney disease: healthcare utilization and survival. BMC Rheumatol. 2019;3(1):11. doi: 10.1186/s41927-019-0060-0.

25. Stamp LK, Taylor W, Gaffo A. Variability in urate-lowering therapy prescribing: a gout, hyperuricemia and crystal-associated disease network (G-CAN) physician survey. J Rheumatol. 2021;48(1):152–153. doi: 10.3899/jrheum.200347.

26. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744–760. doi: 10.1002/acr.24180.

27. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679–687.e1. doi: 10.1016/j.amjmed.2011.09.033.

28. Martino F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–241. doi: 10.1038/nature04516.

29. Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Curr Rheumatol Rep. 2014;16(2):400. doi: 10.1007/s11926-013-0400-9.

30. Ohno I, Ichida K, Okabe H, et al. Frequency of gouty arthritis in patients with end-stage renal disease in Japan. Intern Med. 2005;44(7):706–709. doi: 10.2169/internalmedicine.44.706.

31. Stewart S, Tallon A, Taylor WJ, Gaffo A, Dalbeth N. How flare prevention outcomes are reported in gout studies: a systematic review and content analysis of randomized controlled trials. Semin Arthritis Rheum. 2020;50(2):303–313. doi: 10.1016/j.semarthrit.2019.11.002.

32. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–662. doi: 10.1038/nrrheum.2015.91.

33. Stamp LK, Farquhar H, Pisaniello HL, et al. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. Nat Rev Rheumatol. 2021;17(10):633–641. doi: 10.1038/s41584-021-00657-4.

34. Flores NM, Nuevo J, Klein AB, Baumgartner S, Morlock R. The economic burden of uncontrolled gout: how controlling gout reduces cost. J Med Econ. 2019;22(1):1–6. doi: 10.1080/13696998.2018.1532904.

35. Zobbe K, Prieto-Alhambra D, Cordtz R, et al. Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study. Rheumatology (Oxford) 2019;58:836–9. doi: 10.1093/rheumatology/key390.

36. Kuo C-F, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2015;74:661–7. doi: 10.1136/annrheumdis-2013-204463.

37. Briesacher BA, Andrade SE, Fouayzi H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008;28:437–43. doi: 10.1592/phco.28.4.437.

38. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013;72:826–30. doi: 10.1136/annrheumdis-2012-201676.

39. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894–900. doi: 10.1161/CIRCULATIONAHA.107.703389.

40. Teng GG, Ang L-W, Saag KG, et al. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese health study. Ann Rheum Dis 2012;71:924–8. doi: 10.1136/ard.2011.200523.

41. Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised

controlled trial. Lancet 2018;392:1403–12. doi: 10.1016/S0140-6736(18)32158-5.

42. Perez-Ruiz F, Martínez-Indart L, Carmona L, et al. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 2014;73:177–82. doi: 10.1136/annrheumdis-2012-202421.

43. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012;71:1765–70. doi: 10.1136/annrheumdis-2012-201687.

44. Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016;75:37–44. doi: 10.1136/annrheumdis-2014-206792.

45. Weaver AL. Epidemiology of gout. Cleve Clin J Med 2008;75 Suppl 5:S9–12. doi: 10.3949/ccjm.75.suppl_5.s9.

46. Danish Society of Rheumatology. National guideline for the management of gout [In Danish]. 2021.

47. Bavanendrakumar M, Robinson PC. Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia. Intern Med J 2020;50:337–41. doi: 10.1111/imj.14445.

48. Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63:412–21. doi: 10.1002/art.30119.

49. Rasmussen C, Larsen MB, Linauskas A. Patients with severe gout treated in mixed settings. Dan Med J 2021;68:A06210502.

50. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 2020;16:380–90. doi: 10.1038/s41584-020-0441-1.

51. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis 2012;71:1490–5. doi: 10.1136/annrheumdis-2011-200801.

52. Slot O. Gout in a rheumatology clinic: results of EULAR/ACR guidelines-compliant treatment. Scand J Rheumatol 2018;47:194–7. doi: 10.1080/03009742.2017.1350746.